MDSpire - MDSpire Home

Conexiant

  • July 24, 2026
FDA Approves Acetaminophen/Naproxen Sodium
  • Kathryn Wighton
  • July 24, 2026
  • 2 min
  1. The FDA has approved Tylenol with Naproxen, a fixed-dose combination of acetaminophen and naproxen sodium for over-the-counter use.
  2. The product is indicated for temporary relief of minor aches and pains in adults and pediatric patients aged 12 years and older.
  3. Tylenol with Naproxen is dosed every 12 hours and provides up to 12 hours of pain relief.
  4. The labeling includes warnings about liver damage, stomach bleeding, and increased risk for heart-related issues.
  5. Pregnant or breastfeeding patients are advised to consult a healthcare professional before using the product.
...more

Conexiant

  • July 24, 2026
FDA Approves Furoscix ReadyFlow
  • Kathryn Wighton
  • July 24, 2026
  • 3 min
  1. Furoscix ReadyFlow received FDA approval for treating edema in adults with heart failure or chronic kidney disease.
  2. The product delivers furosemide via a subcutaneous autoinjector, completing administration in 10 seconds or less.
  3. Clinical data showed that Furoscix ReadyFlow met its primary pharmacokinetic endpoint, providing IV-equivalent furosemide exposure.
  4. The safety profile of Furoscix ReadyFlow aligns with known effects of oral and intravenous furosemide.
  5. Common adverse events include administration-site reactions such as bruising, erythema, swelling, and pain.
...more

Conexiant

  • July 24, 2026
Addressing Gaps in HCV Treatment Data
  • Andrea Surnit
  • July 24, 2026
  • 3 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

Conexiant

  • July 24, 2026
Can Risk Infographic Encourage Smoking Cessation in Patients With COPD?
  • Andrea Surnit
  • July 24, 2026
  • 3 min

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Conexiant

  • July 24, 2026
May Kaplan Fiber Injury Signal Greater Knee Instability?
  • Andrea Surnit
  • July 24, 2026
  • 3 min
  1. Kaplan fiber injury was found to be independently associated with greater anterior tibial subluxation in patients with ACL injury.
  2. The study evaluated 132 patients aged 14 to 55 who underwent primary ACL reconstruction and had MRI within 12 weeks of injury.
  3. KF injury was present in 36% of patients and was associated with a higher frequency of concomitant anterolateral ligament injury.
  4. Multivariable analysis showed that KF injury increased anterior tibial subluxation by an average of 3.4 mm.
  5. The study highlights the need for larger, multicenter studies to validate the findings and assess clinical applicability.
...more

Conexiant

  • July 24, 2026
0.3% HA Eye Drops May Improve Dry Eye
  • Andrea Surnit
  • July 24, 2026
  • 3 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

Conexiant

  • July 24, 2026
Plant-Based Diets Linked to Fewer Recurrent UTIs
  • Meg Barbor
  • July 24, 2026
  • 6 min

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Conexiant

  • July 24, 2026
Cannabinoids Fall Short Across Most Psychiatric Disorders
  • Kathryn Wighton
  • July 24, 2026
  • 4 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

The Medicine Maker

  • July 24, 2026
Biopharma Vital Signs – Part 6: Advice for Emerging Biotechs
  • July 24, 2026
  • 13 min
  1. Emerging biotech companies must develop strategies considering manufacturability, funding, and long-term commercial goals.
  2. Selecting the right CRO/CDMO early is crucial to avoid costly revisions and ensure alignment with company goals.
  3. Building a solid scientific foundation and understanding the market landscape are essential for attracting investment.
  4. Engaging experienced partners early can help mitigate risks and improve resource utilization in drug development.
  5. Successful biotechs focus on reducing risk and providing clear value propositions to attract investors and partners.
...more

The Ophthalmologist

  • July 24, 2026
ER-100 Enters Optic Neuropathy Trial
  • July 24, 2026
  • 2 min
  1. Life Biosciences has initiated a Phase 1 clinical trial for ER-100, targeting optic neuropathies such as open-angle glaucoma and NAION.
  2. The trial will assess the safety and tolerability of ER-100, with endpoints focused on visual function.
  3. ER-100 is the first candidate from Life Biosciences’ Epigenetic Restoration platform, utilizing three transcription factors.
  4. Current treatments for open-angle glaucoma do not address retinal ganglion cell damage, while NAION has no approved therapies.
  5. David Sinclair stated that the study is a significant opportunity to test the impact of restoring epigenetic information on human disease.
...more

The Ophthalmologist

  • July 24, 2026
Digital Phenotyping for Retinal Disease
  • July 24, 2026
  • 3 min
  1. A pilot study evaluated the feasibility of digital phenotyping for patients with inherited retinal diseases using the OverSight app.
  2. The study enrolled 25 patients with retinitis pigmentosa and choroideremia, following them for 12 months.
  3. Participants generated a median of 6,087 steps per day, with older individuals typing significantly slower than younger ones.
  4. Completion rates for patient-reported outcome measures exceeded 70 percent, indicating strong engagement with the app.
  5. The study suggests that digital phenotyping could complement traditional assessments by capturing real-world behavioral changes.
...more

Conexiant

  • July 23, 2026
FDA Approves Zidesamtinib for ROS1 Lung Cancer
  • Kathryn Wighton
  • July 23, 2026
  • 2 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

The Pathologist

  • July 23, 2026
When Forensic Pathology Met the Air Ambulance
  • Helen Bristow
  • July 23, 2026
  • 11 min
  1. The Essex & Herts Air Ambulance Trust integrated forensic pathology into its clinical governance, enhancing patient care and clinician well-being.
  2. The partnership arose from a need to bridge gaps in understanding causes of death in prehospital settings, particularly after patient fatalities.
  3. Access to autopsy findings was historically limited due to the separate coronial system, complicating communication between pathologists and air ambulance teams.
  4. Regular case reviews at EHAAT foster a supportive learning environment, allowing clinicians to engage openly without fear of blame.
  5. Autopsy findings help air ambulance teams prioritize injuries during care and improve responses to bereaved families' inquiries about patient outcomes.
...more

The Pathologist

  • July 23, 2026
Hereditary Variant Drives Deadly Prostate Cancer
  • July 23, 2026
  • 3 min
  1. Inherited variants in the CDK12 gene may predispose patients to aggressive metastatic prostate cancer.
  2. The study published in Cancer Discovery challenges the view that CDK12 alterations are only acquired mutations.
  3. Researchers analyzed data from 4,535 patients and found five with inherited truncating CDK12 variants.
  4. All five patients diagnosed with high-grade metastatic prostate cancer had a second somatic CDK12 alteration.
  5. The findings suggest a need to consider CDK12 for hereditary prostate cancer testing and further investigation.
...more

Conexiant

  • July 23, 2026
Conservative Management May Be Safe for Small Mediastinal Lesions
  • Andrea Surnit
  • July 23, 2026
  • 4 min

Get a concise, at-a-glance scorecard that distills clinical guidelines into key recommendations, patient insights, and treatment considerations.

View Scorecard

Conexiant

  • July 23, 2026
Coronal Fracture Reconstruction May Aid Recovery
  • Andrea Surnit
  • July 23, 2026
  • 3 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

Conexiant

  • July 23, 2026
Weekly HIV Therapy Meets Primary Endpoint
  • Kathryn Wighton
  • July 23, 2026
  • 3 min

Objective: To evaluate the efficacy and safety of a once-weekly oral regimen combining islatravir and lenacapavir compared to daily antiretroviral therapy in ad

...more

Conexiant

  • July 23, 2026
Oral Shigella Vaccine Hits 89% Efficacy in Challenge Trial
  • Teraya Smith
  • July 23, 2026
  • 3 min

Objective: To evaluate the efficacy and safety of a live-attenuated oral Shigella sonnei vaccine candidate in a controlled human infection trial. Approach: Tria

...more